trending Market Intelligence /marketintelligence/en/news-insights/trending/9Si2M1sOUxpYTuoDoiFO8g2 content esgSubNav
In This List

Exicure moves to Nasdaq Capital Market, prices $55M public offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Exicure moves to Nasdaq Capital Market, prices $55M public offering

Exicure Inc., a pharmaceutical company specializing in gene regulatory and immunotherapeutic drugs, has uplisted to the Nasdaq Capital Market.

The Skokie, Ill.-based company began trading under the symbol XCUR on July 31.

Exicure also priced a previously announced underwritten public offering of 27,500,000 shares at $2 apiece, with a goal of raising $55 million. The underwriters of the offer have a 30-day option to buy an additional 4,125,000 common shares. The offering is set to close on Aug. 2.

Proceeds from the offering will be used to advance immuno-oncology therapy AST-008 in a phase 1b/2 clinical trial and to develop a Spherical Nucleic Acid, or SNA, therapeutic candidate in a neurology condition. Remaining proceeds will be used for general corporate purposes.

Guggenheim Securities is sole book-running manager for the offering, while Chardan is acting as lead manager. H.C. Wainwright & Co. and Ladenburg Thalmann are co-managers for the offering.